Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 3,500 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $56.14, for a total transaction of $196,490.00. Following the completion of the transaction, the director now owns 86,697 shares in the company, valued at $4,867,169.58. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Lewis Clayton Jr. Cantley also recently made the following trade(s):
- On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.36, for a total value of $507,240.00.
- On Wednesday, June 14th, Lewis Clayton Jr. Cantley sold 2,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $50.87, for a total value of $101,740.00.
- On Thursday, May 25th, Lewis Clayton Jr. Cantley sold 2,036 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $47.10, for a total value of $95,895.60.
Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up 6.087% during mid-day trading on Tuesday, hitting $59.345. The stock had a trading volume of 1,849,420 shares. The firm’s market cap is $2.86 billion. Agios Pharmaceuticals, Inc. has a one year low of $35.84 and a one year high of $67.74. The company has a 50-day moving average of $54.91 and a 200 day moving average of $50.87.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.24. The company had revenue of $10.51 million for the quarter, compared to the consensus estimate of $9.65 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The firm’s revenue for the quarter was down 66.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.64) earnings per share. On average, equities research analysts forecast that Agios Pharmaceuticals, Inc. will post ($6.44) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://stocknewstimes.com/2017/08/01/agios-pharmaceuticals-inc-agio-director-lewis-clayton-jr-cantley-sells-3500-shares-updated.html.
Several large investors have recently modified their holdings of the stock. Blue Sky Asset Management LLC boosted its stake in shares of Agios Pharmaceuticals by 180.7% in the second quarter. Blue Sky Asset Management LLC now owns 6,210 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 3,998 shares during the period. Pictet Asset Management Ltd. boosted its stake in Agios Pharmaceuticals by 13.0% in the second quarter. Pictet Asset Management Ltd. now owns 18,300 shares of the biopharmaceutical company’s stock valued at $854,000 after buying an additional 2,100 shares during the last quarter. TD Asset Management Inc. boosted its stake in Agios Pharmaceuticals by 4.9% in the second quarter. TD Asset Management Inc. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $1,544,000 after buying an additional 1,400 shares during the last quarter. Spark Investment Management LLC boosted its stake in Agios Pharmaceuticals by 139.9% in the second quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock valued at $4,357,000 after buying an additional 49,400 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its stake in Agios Pharmaceuticals by 84.6% in the second quarter. Great West Life Assurance Co. Can now owns 5,543 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 2,541 shares during the last quarter. Institutional investors and hedge funds own 84.24% of the company’s stock.
AGIO has been the subject of several research reports. BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 13th. Cann reaffirmed a “buy” rating and set a $75.00 price target on shares of Agios Pharmaceuticals in a research note on Sunday, June 11th. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, June 11th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 18th. Finally, Zacks Investment Research upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, April 28th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $62.88.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
